Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 687 results for must

  1. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    23 July 2025
    View recommendations

    Sections for TA1079

  2. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

    Medtech innovation briefing
    Published
    16 December 2014

  3. How effective and cost effective are individual, compared with group, education-based interventions for children and young people aged 11 to 18 in full-time education who are thought to be vulnerable to alcohol misuse?

    is best practice. Also, for alcohol education to be successful the pupil must be a willing participant and seeking consent from them (or...

    Research recommendation
    Published
    25 October 2019

  4. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  5. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA345

  6. Thopaz+ portable digital system for managing chest drains (HTG465)

    Evidence-based recommendations on Thopaz+ for managing chest drains.

    HealthTech guidance
    Last updated
    6 June 2022
    View recommendations

    Sections for HTG465

  7. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

    Medtech innovation briefing
    Published
    9 September 2015

  8. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  9. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

    NICE guideline
    Published
    2 September 2025
    View recommendations

    Sections for NG250

  10. Should women having a surgical abortion up to and including 10 +0  weeks' gestation have anti-D prophylaxis if they are RhD (or D) negative?

    systems. This is unnecessary and introduces delays, and means that women must choose between not having testing and prophylaxis or...

    Research recommendation
    Published
    8 November 2019

  11. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA374

  12. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA813

  13. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA766

  14. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  15. Breast cancer (QS12)

    This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    16 June 2016
    View quality statements

    Sections for QS12